Advertisement
Advertisement

CTOR

CTOR logo

Citius Oncology Inc.

1.25
USD
+0.03
+2.46%
Jan 22, 13:25 UTC -5
Closed
...

Citius Oncology Inc. Profile

About

Citius Oncology Inc. platform to develop and commercialize novel targeted oncology therapies. The company is seeking approval from the U.S. Food and Drug Administration of LYMPHIR(TM) for an orphan indication in the treatment of persistent or recurrent cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. Citius Oncology Inc., formerly known as TenX Keane Acquisition, is based in New York.

Info & Links

CEO

Xiaofeng Yuan

Headquarters

420 LEXINGTON AVE, SUITE 2446
NEW YORK, NY 10017, UNITED STATES

Industry

Financial Conglomerates

Sector

Finance

Website

www.citiusonc.com

Auditor

Marcum LLP

Share holders

4

Employees

2

Citius Oncology Inc. Statistics

Valuation Measures

Market Capitalization2

2.95M

Enterprise Value

7.34M

Enterprise Value/EBITDA(ttm)

-8.19

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

1.97

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-100.17%

Return on Invested Capital(ttm)

-80.24%

Return on Assets(ttm)

-15.19%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-896.50K

Net Income Available to Common(ttm)

1.78M

Diluted EPS(ttm)

--

Share Statistics

Beta (5Y Monthly)

-0.64

52-Week Change

-88.55%

S&P 500 52-Week Change

25.48%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

71.55M

Dividend Yield

0.00%

Float4

55.17M

% Held by Insiders

22.90%

% Held by Institutions

70.52%

Balance Sheet

Total Cash(mrq)

100.00

Total Cash Per Share(mrq)

0.00

Total Debt(mrq)

4.39M

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

--

Quick Ratio(mrq)

0.08%

Book Value Per Share(mrq)

--

Cash Flow

Operating Cash Flow Per Share(ytd)

--

Free Cash Flow(ytd)

0.00

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement